CCM
ASMB icon

Consonance Capital Management’s Assembly Biosciences ASMB Stock Holding History

Consonance Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-164,156
Closed -$11.9M – 38
2020
Q4 		$11.9M Hold
164,156
– – 1.11% 23
2020
Q3 		$32.4M Sell
164,156
-100,472
-38% -$25.3M 3.95% 12
2020
Q2 		$74.1M Hold
264,628
– – 4.44% 12
2020
Q1 		$47.1M Buy
264,628
+108,095
+69% +$23.2M 3.51% 12
2019
Q4 		$38.4M Buy
+156,533
New +$28.8M 2.35% 19

Other funds holding ASMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Consonance Capital Management's ASMB Position: Q1 2021 in Review

Consonance Capital Management sold out of Assembly Biosciences (ASMB) in Q1 2021, closing a stake of 164,156 shares — an estimated $11.9M sold.

Consonance Capital Management first reported a position in ASMB in Q4 2019 and held it in 5 quarters. The position peaked at $74.1M in Q2 2020. 107 funds tracked by Wall St. Rank hold ASMB as of Q1 2021.

  • Consonance Capital Management reported no remaining Assembly Biosciences position as of Q1 2021 after selling out during the quarter.
  • Consonance Capital Management sold 164,156 Assembly Biosciences shares in Q1 2021, an estimated $11.9M.
  • Consonance Capital Management first reported a position in Assembly Biosciences in Q4 2019 and held it in 5 quarters.
  • Consonance Capital Management's Assembly Biosciences position peaked at $74.1M in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2021.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.